Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch from intravenous infliximab to subcutaneous CT-P13 in established inflammatory bowel disease and inflammatory arthritis
ISRCTN13323475Phase 4Completed
- Sponsor
- University Hospital Southampton NHS Foundation Trust
- Start
- Feb 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 4, open-label, single-arm trial of infliximab-dyyb and infliximab in Crohn's disease, autoimmune colitis, rheumatoid arthritis (RA) and 2 more, sponsored by University Hospital Southampton NHS Foundation Trust. Primary endpoints: Maintenance of clinical status in Crohn's disease, Maintenance of clinical status in ulcerative colitis and 2 more. Started Feb 2021; status: completed.
02
Drugs
infliximab-dyybinfliximab
03
Conditions
Crohn's diseaseautoimmune colitisrheumatoid arthritis (RA)psoriatic arthritis (PsA)ankylosing spondylitis (AS)
Beyond the preview
Go deeper on ISRCTN13323475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN13323475.